Ryanodine receptor inhibition with acute dantrolene treatment reduces arrhythmia susceptibility in human hearts-Reference-Cited by-同舟云学术

Ryanodine receptor inhibition with acute dantrolene treatment reduces arrhythmia susceptibility in human hearts

Published:2023-10-01 Issue:4 Volume:325 Page:H720-H728
ISSN:0363-6135
Container-title:American Journal of Physiology-Heart and Circulatory Physiology
language:en
Short-container-title:American Journal of Physiology-Heart and Circulatory Physiology

Author:

George Sharon A.¹²^ORCID,Brennan-McLean Jaclyn A.¹,Trampel Katy A.¹²^ORCID,Rytkin Eric¹²^ORCID,Faye N. Rokhaya¹^ORCID,Knollmann Bjorn C.³^ORCID,Efimov Igor R.¹²^ORCID

Affiliation:

1. Department of Biomedical Engineering, George Washington University, Washington, District of Columbia, United States

2. Department of Biomedical Engineering, Northwestern University, Chicago, Illinois, United States

3. Vanderbilt Center for Arrhythmia Research and Therapeutics, Vanderbilt University School of Medicine, Nashville, Tennessee, United States

Abstract

Ryanodine receptor 2 hyperactivity is observed in structural heart diseases caused by ischemia or heart failure. It causes abnormal calcium leaks, which can trigger arrhythmias. To prevent arrhythmias, we applied dantrolene in human hearts ex vivo. Isoproterenol and caffeine treatment increased PVC incidence, whereas dantrolene reduced the PVC burden. Dantrolene treatment suppresses triggers and reverses arrhythmogenic substrates and could be a novel antiarrhythmic therapy in patients with structural heart disease.

Funder

American Heart Association

Publisher

American Physiological Society

Subject

Physiology (medical),Cardiology and Cardiovascular Medicine,Physiology

Link

https://journals.physiology.org/doi/pdf/10.1152/ajpheart.00103.2023

Reference51 articles.

1. Defining structural heart disease in the adult patient: current scope, inherent challenges and future directions

2. RyR2 inhibition with dantrolene is antiarrhythmic, prevents further pathological remodeling, and improves cardiac function in chronic ischemic heart disease

3. Ventricular Tachycardia in Structural Heart Disease